Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: The value of early evaluation of the course of the disease

Rizzoli | R. Fanin | P. Galieni | M. Baccarani | T. Barbui | F. Mandelli | A. Pileri | G. Papa | M. Marangolo | G. Rosti | E. Ascari | C. Musolino | M. Aglietta | L. Mangoni | A. Gallamini | G. Squadrito | F. Grignani | A. Difrancesco | G. Lucarelli | A. Nosari | E. Morra | T. Diperri | S. Tura | D. Quaglino | G. Pinotti | D. Russo | N. Testoni | F. Pasini | A. Ambrosetti | A. Riccardi | G. Alimena | G. Specchia | A. Liberati | B. Rotoli | P. Ferrini | P. Avanzini | R. Landolfi | B. Bizzi | F. Dore | F. Decataldo | P. Leoni | G. Danieli | R. Cimino | F. Leoni | E. Miraglia | D. Damiani | T. Izzi | E. Dini | P. Coser | M. Michieli | E. Bianchini | P. Guglielmi | S. Nardelli | F. Papineschi | G. Spremolla | M. Cantonetti | P. Iacopino | I. Majolino | M. Martelli | F. Gavosto | A. Zaccaria | F. Nobile | G. Castoldi | L. Prossomariti | G. Broccia | C. Bernasconi | E. Cacciola | G. Sparaventi | I. Gentilini | M. Fiacchini | F. Ricciuti | L. Bruzzese | A. Pinto | R. Battista | S. Rotondo | E. Gallo | F. Caronia | A. Montuoro | C. Derosa | E. Montefusco | E. Zuffa | M. Monaco | M. Carotenuto | D. Zamagni | G. Perona | A. Cajozzo | P. Foa | A. Capucci | M. Lombardo | A. Abbadessa | G. Scapoli | M. Maiolo | G. Sala | L. Resegotti | M. Pizzuti | D. Dini | C. Bodenizza | S. Morandi | B. Comotti | G. Torlontano | L. Deriu | F. Buffa | R. Perricone | F. Ciccone | F. Paolino | R. Montuori | Liso | E. Dispensa | M. Longinotti | Zagonel | R. Debiase | L. Luciano | F. Gobbi | U. Diprisco | A. Delaurenzi | A. Miliani

[1]  R. Gale,et al.  Bone marrow transplantation in chronic myelogenous leukemia. , 1992, Seminars in hematology.

[2]  Y. C. Chen,et al.  Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease , 1990, British journal of haematology.

[3]  L. Tomatis,et al.  Cancer Mortality in Italy , 1990, Tumori.

[4]  P. Martiat,et al.  The position of the M‐BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia , 1990, British journal of haematology.

[5]  T. Lion,et al.  Duration of first remission as an indicator of long‐term survival in chronic myelogenous leukaemia , 1989, British journal of haematology.

[6]  K. Mills,et al.  The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. , 1988, Blood.

[7]  R. Kurzrock,et al.  Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. , 1988, Blood.

[8]  D. Russo.  Prospective confirmation of a prognostic classification for Ph + chronic myeloid leukaemia , 1988, British journal of haematology.

[9]  R. Gale,et al.  Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. , 1988, Blood.

[10]  M. Lichtman,et al.  Variables influencing the timing of marrow transplantation in patients with chronic myelogenous leukemia. , 1986, Blood.

[11]  A. Levis,et al.  Peripheral erythroid precursor and prognosis in chronic granulocytic leukemia , 1986, Cancer.

[12]  C. la Vecchia,et al.  Cancer Mortality in Italy, 1980 , 1986, Tumori.

[13]  M. Baccarani,et al.  Chronic myeloid leukemia. , 1986, Haematologica.

[14]  E. Gehan,et al.  Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.

[15]  Š.,et al.  Randomized trial of splenectomy in Ph1‐positive chronic granulocytic leukaemia, including an analysis of prognostic features , 1983, British journal of haematology.

[16]  S Oguma,et al.  Factors influencing survival in philadelphia chromosome positive chronic myelocytic leukemia , 1982, Cancer.

[17]  C. Rozman,et al.  A multivariate analysis of prognostic factors in chronic myeloid leukemia. , 1982, Blood.

[18]  Goldman Jm,et al.  New approaches in chronic granulocytic leukemia--origin, prognosis, and treatment. , 1982 .

[19]  G A Gomez,et al.  Prognostic features at diagnosis of chronic myelocytic leukemia , 1981, Cancer.

[20]  M. Baccarani,et al.  Staging of Chronic Myeloid Leukaemia , 1981, British journal of haematology.

[21]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[22]  D. Bergsagel.  The chronic leukemias: a review of disease manifestations and the aims of therapy. , 1967, Canadian Medical Association journal.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  N. Wareham,et al.  Relationship of the duration of the chronic phase in chronic granulocytic leukaemia to the need for treatment during the first year after diagnosis , 2004, Cancer Chemotherapy and Pharmacology.

[25]  S. Morris,et al.  Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. , 1990, Blood.

[26]  H. Kantarjian,et al.  Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. , 1990, The American journal of medicine.

[27]  M. Baccarani,et al.  Staging and prognosis in chronic myelogenous leukemia. , 1988, Seminars in hematology.

[28]  R. Kurzrock,et al.  Therapy of chronic myelogenous leukemia: chemotherapy and interferons. , 1988, Seminars in hematology.

[29]  J. Sokal,et al.  Survival in Ph1-positive chronic myelocytic leukemia: relationship to findings at diagnosis and to disease kinetics after the first course of treatment. , 1985, Leukemia research.

[30]  D.,et al.  Regression Models and Life-Tables , 2022 .